Anika Therapeutics Remains On Course In Transition Year

Anika Therapeutics' logo

Anika Therapeutics reported 2Q21 orthopedic revenue of $36.2 million, +25.4% vs. 2Q20. Compared to the same period in 2019, the company's orthopedic revenue grew +32% on the strength of joint preservation products acquired from Parcus and Arthosurface. Anika's legacy joint pain management franchise declined -8.7% compared to 2Q19.


document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us